Hayato Yokota

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Epidermal Growth Factor Receptor

Combination Therapy

Patient Reported

Small Cell Lung Cancer

Top Venues

Journal of clinical pharmacy and therapeutics

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura
Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysis. Cancer chemotherapy and pharmacology (2023)
Tatsuro Fukuhara, Kazuhiro Imai, Taku Nakagawa, Ryotaro Igusa, Hayato Yokota, Kana Watanabe, Aya Suzuki, Mami Morita, Ren Onodera, Akira Inoue, Masatomo Miura, Yoshihiro Minamiya, Makoto Maemondo
A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety. Biomedicines 11 (9) (2023)
Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura
Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer. Biology 10 (10) (2021)
Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura
Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer. Journal of clinical pharmacy and therapeutics 45 (4) (2020)